Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KN026 |
Synonyms | |
Therapy Description |
KN026 is a bispecific ERBB2 (HER2) antibody that inhibits Erbb2 (Her2) heterodimerization, potentially resulting in decreased downstream signal activation and induction of cytotoxicity against Erbb2 (Her2)-overexpressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KN026 | KN-026|KN 026 | HER2 (ERBB2) Antibody 76 | KN026 is a bispecific ERBB2 (HER2) antibody that inhibits Erbb2 (Her2) heterodimerization, potentially resulting in decreased downstream signal activation and induction of cytotoxicity against Erbb2 (Her2)-overexpressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03847168 | Phase I | KN026 | KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer | Unknown status | USA | 0 |